These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 3510761)
21. Autonomic mechanisms and sudden death. New insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction. Schwartz PJ; Vanoli E; Stramba-Badiale M; De Ferrari GM; Billman GE; Foreman RD Circulation; 1988 Oct; 78(4):969-79. PubMed ID: 3168199 [TBL] [Abstract][Full Text] [Related]
22. Different effects of epoprostenol on ischemia-induced ventricular arrhythmias in dogs. Puddu PE; Langlet F; Lanti M; Guillen JC; Dawodu AA; Monti F; Schiariti M; Reale A Cardiologia; 1990 Jul; 35(7):551-9. PubMed ID: 2088600 [TBL] [Abstract][Full Text] [Related]
23. Epoprostenol (PGI2) reduces the incidence of post-reperfusion ventricular fibrillation in the dog. Jouve R; Puddu PE; Langlet F; Guillen JC; Serradimigni A Cardiologia; 1985 Feb; 30(2):91-7. PubMed ID: 3905005 [No Abstract] [Full Text] [Related]
24. Amelioration of the deleterious effects of platelets activated during cardiopulmonary bypass. Comparison of a thromboxane synthetase inhibitor and a prostacyclin analogue. Huddleston CB; Hammon JW; Wareing TH; Lupinetti FM; Clanton JA; Collins JC; Bender HW J Thorac Cardiovasc Surg; 1985 Feb; 89(2):190-5. PubMed ID: 2578591 [TBL] [Abstract][Full Text] [Related]
25. Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity. Murakami M; Kinukawa M; Kanazawa T; Maruyama K; Miyagi M; Miyata H; Ujiie A J Pharmacol Exp Ther; 1996 Nov; 279(2):877-83. PubMed ID: 8930195 [TBL] [Abstract][Full Text] [Related]
26. Cicletanide improves outcome after left circumflex coronary artery occlusion-reperfusion in the dog. Jouve R; Langlet F; Puddu PE; Rolland PH; Guillen JC; Cano JP; Serradimigni A J Cardiovasc Pharmacol; 1986; 8(1):208-15. PubMed ID: 2419686 [TBL] [Abstract][Full Text] [Related]
27. Influence of the thromboxane synthetase inhibitor HOE 944, prostacyclin and indomethacin on reperfusion arrhythmias, cardiodynamics and metabolism in isolated ischemic rat hearts. Linz W; Lau HH; Beck G; Schökens BA Biomed Biochim Acta; 1988; 47(10-11):S23-6. PubMed ID: 3073762 [TBL] [Abstract][Full Text] [Related]
28. Protective effect of verapamil on vulnerability to ventricular fibrillation during myocardial ischaemia and reperfusion. Brooks WW; Verrier RL; Lown B Cardiovasc Res; 1980 May; 14(5):295-302. PubMed ID: 7388861 [TBL] [Abstract][Full Text] [Related]
29. Comparison of the effects of a thromboxane synthase inhibitor or prostacyclin in combination with a phosphodiesterase inhibitor for prevention of experimental thrombosis and sudden death in rabbits. Smith EF; Egan JW J Pharmacol Exp Ther; 1987 Jun; 241(3):855-60. PubMed ID: 3298621 [TBL] [Abstract][Full Text] [Related]
30. Effects of chronic hypertension and left ventricular hypertrophy on the incidence of sudden cardiac death after coronary artery occlusion in conscious dogs. Koyanagi S; Eastham C; Marcus ML Circulation; 1982 Jun; 65(6):1192-7. PubMed ID: 6210460 [TBL] [Abstract][Full Text] [Related]
31. Effect of nitroglycerin on vulnerability to ventricular fibrillation during myocardial ischemia and reperfusion. Stockman MB; Verrier RL; Lown B Am J Cardiol; 1979 Feb; 43(2):233-8. PubMed ID: 104608 [TBL] [Abstract][Full Text] [Related]
33. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis. Aiken JW; Shebuski RJ; Miller OV; Gorman RR J Pharmacol Exp Ther; 1981 Nov; 219(2):299-308. PubMed ID: 6270303 [No Abstract] [Full Text] [Related]
34. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis. Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320 [TBL] [Abstract][Full Text] [Related]
36. Beta2-adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence for enhanced sensitivity to beta2-adrenergic stimulation in animals susceptible to sudden death. Billman GE; Castillo LC; Hensley J; Hohl CM; Altschuld RA Circulation; 1997 Sep; 96(6):1914-22. PubMed ID: 9323081 [TBL] [Abstract][Full Text] [Related]
37. Prevention of sudden cardiac death by dietary pure omega-3 polyunsaturated fatty acids in dogs. Billman GE; Kang JX; Leaf A Circulation; 1999 May; 99(18):2452-7. PubMed ID: 10318669 [TBL] [Abstract][Full Text] [Related]
38. Influence of intracoronary platelet aggregation on ventricular electrical properties during partial coronary artery stenosis. Kowey PR; Verrier RL; Lown B; Handin RI Am J Cardiol; 1983 Feb; 51(3):596-602. PubMed ID: 6186137 [TBL] [Abstract][Full Text] [Related]
39. [Structural and functional bases of the mechanisms of myocardial fibrillation in sudden cardiac death]. Kakturskiĭ LV Arkh Patol; 1985; 47(1):86-91. PubMed ID: 2983646 [TBL] [Abstract][Full Text] [Related]
40. [Participation of the prostacyclin-thromboxane system in the mechanisms of prevention of arrhythmia caused by occlusion of the coronary artery in adapted rats]. Maslov LN; Khaliulin IG; Dvurechenskaia GIa; Barabash NA; Lishmanov IuB Biull Eksp Biol Med; 1991 Jan; 111(1):16-8. PubMed ID: 1711383 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]